FeesSafety
Pluang+

Eli Lilly's Q3 volume growth beats pricing pressure, raising 2026 revenue guidance with a $1,600 price target.

Analyst Insights
19 Nov 2026, 11:11 WIB
Seeking Alpha
View Source
Bullish
Eli Lilly's Q3 volume growth beats pricing pressure, raising 2026 revenue guidance with a $1,600 price target.

Eli Lilly reported a 53% volume increase in Q3 despite a 15% drop in realized prices, prompting management to raise 2026 revenue guidance to $91–92 billion. The company's promising drug Retatrutide, currently in Phase 3 trials, supports future growth with an expected BLA submission in Q1 2027, although regulatory and manufacturing risks remain. The $1,600 price target values the stock at 29 times estimated 2027 earnings per share of $55, supported by strong cash flow for continued investment. Risks include oral drug persistence and potential generic competition.

Eli Lilly shares are trading at USD 1,372.35 on Pluang, down 0.74% for the day, reflecting cautious investor sentiment despite strong volume and growth prospects. As of Nov 19, 2026 16:21 WIB, the stock shows a market cap of $1.26 trillion and a typical hold time of 95 days on the platform.

More News (LLY)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App